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ABSTRACT 
Simple, cost effective, precise and accurate UV-Spectrophotometric method for estimation of Enoxaparin sodium was developed and validated 
as per ICH guidelines. This Method involves solving of calibration curve based on measurement of absorbance wavelengths 234nm in 0.1 N HCl. 
The method obeys the Beer’s law in the concentration ranges 100-500µg/ml. The developed method was validated according to ICH guidelines 
and values of accuracy, precision and other statistical analysis were found to be in good accordance with the prescribed values. % Recovery for 
both the drugs were in the range of 99.288 99.632% indicating excellent accuracy with percentage RSD Values less than 2. The method was 
precise, with a relative standard deviation of less than 2% for all tha validation parameters. Thus, method can be used for routine monitoring of 
drugs in industry for the assay of bulk drugs and commercials. 
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INTRODUCTION 
Enoxaparin sodium belongs to the group of low molecular 
weight heparins chemically it is 6-[5-acetamido-4,6-
dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-3-[5-(6-
carboxy-4,5-dihydroxy-3-sulfooxyoxan-2-yl)oxy-6-(hydroxyl 
methyl)-3-(sulfoamino)-4-sulfooxyoxan-2-yl]oxy-4-hydroxy-
5-sulfooxyoxane-2-carboxylic acid1. The empirical formula 
of Enoxaparin sodium is C42H59N3Na4O35S2 and its molecular 
weight is 1322.000 g/mol, Brands: Lovenox Injection (150 
mg), structural formula (Fig. 1). Enoxaparin sodium is a 
white crystaline powder. It is practically soluble in water 
and freely soluble in 0.1 N HCl. It also dissolves freely in 
Ethanol, methanol, dissolves sparingly in Phosphate Buffer 
pH 6.8. Enoxaparin sodium has a greater bioavailability and 
longer half-life than unfractionated heparin, permitting less 
frequent subcutaneous administration. In well controlled 
trials in surgical patients at high risk of deep venous 
thrombosis (DVT)2.  
In clinical studies, Enoxaparin sodium has also prevented 
coagulation of extracorporeal circulation, maintaining the 
 
patency  of  the  circuit  in  patients  undergoing  haemodialysis. 
Thus, Enoxaparin sodium represents an effective alternativein 
the   prophylaxis   and   treatment   of   thrombosis,  with   the 
convenience   of   less   frequent   administration   than 
unfractionated   heparin   and   the   possible   advantage   of   a 
lesser   propensity   for   bleeding   complications.  Enoxaparin 
sodium  injections  are  available  in  market  with  brand  name 
Lovenox   (150  mg),  Critnox   (60 mg),  Venoxtaj   (80  mg)  and 
many   other   brands   are   available   in   the  market3. Literature 
survey  reveals  that very  few methods4-5 are  available  for  the 
estimation   of Enoxaparin   sodium   alone   or in   combination 
with   other   drugs   and   in   its   dosage   form. In   the   present 
study, an  attempt  was made  to  develop a  simple, precise  and 
accurate  method  for  the  estimation  of  drug  in  pharmaceutical  
dosage  form  and  validate  as  per  International  Conference  on 
Harmonization (ICH) guidelines6.
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Fig. 1: Structural formula of Enoxaparin sodium  
       
EXPERIMENTAL 
Reagents and chemicals 
Enoxaparin sodium pure drug was obtained as a gift sample 
from Cipla Private Limited (Goa, India). Lovenox Injection 
(150 mg), were purchased from local market. Methanol, 
acetonitrile were procured from Rankem, RFCL Limited, New 
Delhi, India. Milli Q water was used throughout the study. 
Other chemicals used were of analytical or HPLC grade. 
Apparatus 
Spectral analysis were made on a Labindia 
spectrophotometer, Model- 3000 Plus, was employed with 
spectral bandwidth of 1 nm and wavelength accuracy of ± 0.3 
nm with automatic wavelength correction with a pair of 10 
mm quartz cells. Glassware used in each procedure were 
soaked overnight in a mixture of chromic acid and sulphuric 
acid rinsed thoroughly with double distilled water and dried 
in hot air oven. 
Method Development 
Standard stock solution 
Accurately weighed Enoxaparin sodium (100 mg) was 
transferred to a 100 mL volumetric flask, dissolved in 80 mL 
0.1 N HCl.  The flask was sonicated for about 10 min to 
solubilize the drug and the volume was made up to the mark 
100ml with 0.1N HCl to get a concentration of 1000 µg/ml. 
Selection of wavelength for linearity 
Solutions of 100g/ml of Enoxaparin sodium were prepared 
and the solution was scanned in the spectrum mode from 
200 nm to 400 nm. The maximum absorbance of Enoxaparin 
sodium was observed at 234.0 nm. Enoxaparin sodium 
showed linearity in the concentration range of 100-500 
g/ml at their respective maxima. They were scanned in the 
wavelength range of 200-400 nm and the overlain spectrum 
was obtained (Fig.-2&3). 
Preparation of calibration curve  
1.0ml, 2.0ml, 3.0ml, 4.0ml and 5.0ml from stock solution 
were taken separately in 10 ml volumetric flask and volume 
was made up to 10 ml with 0.1N HCl. This gave the solutions 
of 100µg/ml, 200µg/ml, 300µg/ml, 400µg/ml and 500µg/ml 
respectively for Enoxaparin sodium. Triplicate dilutions of 
drug solutions were prepared and the prepared working 
solutions of Enoxaparin sodium were scanned 234nm. The 
absorbance’s were recorded and were plotted against the 
concentrations to obtain their respective calibration curves. 
 
 
 
Fig 2: Determination of λmax of Enoxaparin sodium  
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Fig 3: 3D graph of Determination of λmax of Enoxaparin sodium 
 
Methods validation  
Validation of the method was carried out in accordance with 
the International Conference on Harmonization Q2B 
guidelines 20059.  
Linearity  
The linearity of analytical method was carried out to check 
its ability to elicit test results that are proportional to the 
concentration of analyte in sample within a given range. 
Different levels of standard solutions were prepared and 
estimate into the UV and the results was recorded. The 
results of linearity are reported in Table 1. 
Accuracy 
The accuracy of the proposed methods was assessed by 
recovery studies at three different levels i.e. 80%, 100%, 
120%. The recovery studies were carried out by adding 
known amount of standard solution of Enoxaparin sodium to 
preanalysed sample solutions. The resulting solutions were 
then re-analysed by proposed methods. Whole analysis 
procedure was repeated to find out the recovery of the 
added drug sample. This recovery analysis was repeated at 
3 replicate of 5 concentrations levels. The results of linearity 
are reported in Table 1 
Precision 
Precision was determined by repeatability and Intermediate 
precision of drug. Repeatability result indicates the precision 
under the same operating condition over short interval time. 
The intermediate precision study is expressed within 
laboratory variation on different days and analyst to analyst 
variation by different analyst. The value of SD and %RSD are 
less than 2 indicate the precision of method. Result of 
precision shown in Table 4. 
Analysis of injectable formulation 
Lovenox Injection amount equivalent to 150mg (1.0ml) was 
taken in 150 ml volumetric flask. Then 5ml of 0.1 N HCl was 
added and the flask was sonicated for about 10 min to 
solubilize the drug present in tablet powder and the 
volume was made up to the mark with 0.1 N HCl. After 
sonication filtration was done through Whatman filter 
paper No. 41. Filtrate was collected and further diluted with 
0.1 N HCl to get the final concentrations of drug in the 
working range. The absorbances of final dilutions were 
observed at selected wavelength and the concentration was 
obtained from calibration curve method. The procedure was 
repeated for five times. Result of Assay shown in Table 5. 
Table 1: Results of linearity of ENXP   
Parameter Enxp 
Concentration (μg/ml) 100-500 
Correlation Coefficient (r2)* 0.999 
Slope (m)* 0.001 
Intercept (c)* 0.002 
*Value of five replicate and five concentrations 
 
Table 2: Results of recovery study 
% Level % Mean±SD* 
80% 99.632±0.148 
100% 99.288±0.123 
120% 99.561±0.225 
* Value of three replicate and five concentrations 
 
Table 3: Results of precision 
Parameter % Mean±SD* 
Repeatability 99.577±1.178 
Intermediate precision 
Day to day precision 99.266±1.083 
Analyst-to-Analyst  99.270±1.154 
Reproducibility 99.259±1.082 
* Value of five replicate and five concentrations 
 
Table 4: Assay of injectable formulation 
Conc. Present (µg/ml) % Conc. Found (Mean) 
100 99.08 
200 99.62 
300 99.26 
400 99.26 
500 99.84 
*Average of three replicate and five concentrations 
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RESULTS AND DISCUSSION 
Method development by UV-Spectrophotometer is cost 
effective and time saving as compared to HPLC method of 
analysis. Thus, for estimation of routine sample of drugs 
simple, rapid, sensitive and accurate analytical UV methods 
were utilized which reduces unnecessary tedious sample 
preparations and use of costly materials. To develop suitable 
methods of analysis, various solvents were studied. Based on 
sensitivity of the method and non-toxic behaviour 0.1 N HCl 
was selected as a solvent for the methods. The method obeys 
the Beer’s law in the concentration ranges 100-500µg/ml 
with R2 value 0.999. The recovery was found between 
99.288±0.123 to 99.632±0.148% with RSD value less than 2. 
The standard deviation, coefficient of variance and standard 
error were obtained for Enoxaparin sodium was 
satisfactorily low. Result of precision at different levels was 
found to be within acceptable limits (RSD < 2). Thus, the 
method provides a simple, convenient, rapid and accurate 
way to determine ENXP in marketed formulation. 
CONCLUSION 
The developed UV spectrophotometric method for the 
estimation of Enoxaparin sodium was found to be simple and 
useful with high accuracy, precision and repeatability. 
Sample recoveries in all formulations using the above 
method was in good agreement with their respective label 
  
 
 
  
   
 
  
 
 
 
  
 
 
 
 
 
 
 
claim  or  theoretical  drug  content;  thus,  suggesting  the 
validity  of  the  method  and  non-interference  of  formulation 
excipients  in  the  estimation.  In  the  selected  solvent  system
(0.1 N HCl), drugs were stable. Thus, suggesting that samples 
need  not  be  estimated  immediately  after  collection.  The 
developed  method  was  found  to  be  stability  specific  and 
were  validated  as  per  ICH  guidelines  (1994,  1996  and
2005) and statistical method.
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